The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Open accessAbstract
The development of targeted medicine has greatly expanded treatment options and spurred new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging as a prevalent treatment in recent years. With mixed clinical success, mAbs still hold significant shortcomings, as they possess limited tumor penetration, high manufacturing costs, and the potential to develop therapeutic resistance. However, the recent discovery of "nanobodies," the smallest-known functional antibody fragment, has demonstrated significant translational potential in preclinical and clinical studies. This review highlights their various applications in cancer and analyzes their trajectory toward their translation into the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Chowdhury, S., Castro, S., Coker, C., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0498-z · Cited by 724
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S., & Wyns, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505379103 · Cited by 676
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Cataland, S., Knöbl, P., Wu, H., Artoni, A., Westwood, J.-P., Mansouri Taleghani, M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 666
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O’Rourke, T., Narayanan, S., Papadopoulos, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02018 · Cited by 599
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Liu, J. K. H. (2014) · Annals of Medicine & Surgery · doi:10.1016/j.amsu.2014.09.001 · Cited by 515
Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. R. G., & Hamers, R. (1994) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/7.9.1129 · Cited by 494
Cited by
Engineering protein-based therapeutics through structural and chemical design
Ebrahimi, S. B., & Samanta, D. (2023) · Nature Communications · doi:10.1038/s41467-023-38039-x · Cited by 382
NANOBODIES®: A Review of Diagnostic and Therapeutic Applications
Jin, B.-K., Odongo, S., Radwanska, M., & Magez, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065994 · Cited by 371
ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins
Abanades, B., Wong, W. K., Boyles, F., Georges, G., Bujotzek, A., & Deane, C. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04927-7 · Cited by 298
Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation
Zhang, H., Han, Y., Yang, Y., Lin, F., Li, K., Kong, L., Liu, H., Dang, Y., Lin, J., & Chen, P. R. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08521 · Cited by 292
Structural Modeling of Nanobodies: A Benchmark of State-of-the-Art Artificial Intelligence Programs
(2023) · doi:10.3390/molecules28103991 · Cited by 39
Metadata
- Authors
- Yang, E. Y., & Shah, K.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-23
- Volume
- 10
- Pages
- 1182-1182
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3044721763
- Cited by
- 291
- References
- 212
- FWCI
- 20.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. https://app.cochat.ai/papers/10.3389/fonc.2020.01182
- The paper
- Yang, E. Y., & Shah, K. (2020). Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.01182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.